Analysts Anticipate Growth for iShares U.S. Real Estate ETF
In a review of ETFs within our coverage, ETF Channel has analyzed the trading prices of underlying holdings compared to the average analyst 12-month forward target prices. For the iShares U.S. Real Estate ETF (Symbol: IYR), the implied analyst target price is $106.78 per unit.
Currently, IYR is trading at approximately $94.86 per unit. This indicates a potential upside of 12.56%, based on the average target prices of its underlying holdings. Noteworthy among these holdings are Sabra Health Care REIT Inc. (Symbol: SBRA), Omega Healthcare Investors, Inc. (Symbol: OHI), and Starwood Property Trust Inc. (Symbol: STWD). Specifically, SBRA’s recent price of $17.28/share has an analyst target 13.57% higher at $19.62/share. Similarly, OHI shows a 12.95% upside from its current price of $36.18 with a target of $40.87/share. Analysts expect STWD to reach a target of $21.57/share, reflecting a 12.64% increase from its current price of $19.15. Below is a chart showing the twelve-month price history for SBRA, OHI, and STWD:
Here’s a summary table of the current analyst target prices:
| Name | Symbol | Recent Price | Avg. Analyst 12-Mo. Target | % Upside to Target |
|---|---|---|---|---|
| iShares U.S. Real Estate ETF | IYR | $94.86 | $106.78 | 12.56% |
| Sabra Health Care REIT Inc | SBRA | $17.28 | $19.62 | 13.57% |
| Omega Healthcare Investors, Inc. | OHI | $36.18 | $40.87 | 12.95% |
| Starwood Property Trust Inc. | STWD | $19.15 | $21.57 | 12.64% |
These analyst targets bring to light questions about their validity. Are analysts justified in their optimistic outlook, or are they too aggressive in their predictions? A high price target relative to a stock’s current position may signify future potential but might also lead to downward adjustments if market conditions shift. This presents an opportunity for investors to conduct further research.
10 ETFs With Most Upside To Analyst Targets »
Also see:
• Institutional Holders of PQ
• ESAB Average Annual Return
• PAI Insider Buying
The views and opinions expressed herein are solely those of the author and do not necessarily reflect those of Nasdaq, Inc.
